SINOPHARM TECH (08156) announced its annual results for the year ended June 30, 2025, reporting revenue of approximately HK$61.3 million, representing an increase of about 48% compared to the previous year. The loss attributable to owners of the company was approximately HK$0.9 million, a substantial decrease of about 95% year-on-year. The loss per share stood at HK$0.19 cents.

According to the announcement, the revenue growth was primarily attributable to increased market demand for healthcare products and improved operational efficiency in supply chain services, highlighting the effectiveness of the company's strategic focus on these core business areas.

The Board of Directors believes that the Group's significant improvement in financial performance for the year was mainly due to the net impact of the following factors: (i) gross profit increased by approximately HK$9.2 million or 184% year-on-year due to business improvements; (ii) enhanced cost control over administrative and operational expenses; (iii) debt capitalization gains of approximately HK$3.9 million during the year; and (iv) reduced financing costs due to debt capitalization during the year.